Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lee Haas

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1598113433 CMS profile 10880483

501 S 2Nd St, Louisville, KY 40202

Open in the dashboard

General payments

$95,092

807 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lee Haas of Louisville, KY is reported in the CMS Open Payments database as having received $95,092 across 807 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,985 160
2024 General $20,461 165
2023 General $29,318 219
2022 General $16,618 162
2021 General $1,711 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Haas
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lee Haas were reported at $26,985. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lee Haas Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,711 $135 $40–$426 $132
2022 $16,618 $152 $48–$470 $149
2023 $29,318 $166 $54–$529 $160
2024 $20,461 $173 $55–$556 $164
2025 $26,985 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $71,959 203 payments
  2. E.R. Squibb & Sons, L.L.C. $6,450 44 payments
  3. UCB, Inc. $3,958 102 payments
  4. Eli Lilly and Company $3,638 6 payments
  5. AbbVie, Inc. $2,389 168 payments
  6. Janssen Biotech, Inc. $1,860 24 payments
  7. Novartis Pharmaceuticals Corporation $1,472 87 payments
  8. Galderma Laboratories, L.P. $655 23 payments
  9. Regeneron Healthcare Solutions, Inc. $553 28 payments
  10. Sun Pharmaceutical Industries Inc. $450 19 payments
  11. Other $1,709 103 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $67,992 79 payments
  2. Food and Beverage $12,723 677 payments
  3. Consulting Fee $7,658 7 payments
  4. Travel and Lodging $6,039 34 payments
  5. Education $681 10 payments
Products named General payments · program years 2021–2025
  1. EBGLYSS $33,963 72 payments
  2. OLUMIANT $20,537 65 payments
  3. TALTZ $13,999 83 payments
  4. SOTYKTU $4,905 41 payments
  5. Bimzelx $2,960 49 payments
  6. TREMFYA $1,753 19 payments
  7. SKYRIZI $1,433 98 payments
  8. Cimzia $971 51 payments
  9. COSENTYX Immunology $532 32 payments
  10. COSENTYX Dermatology $518 26 payments
  11. Other $5,447 288 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

760

Median for Nurse Practitioner: 389

Drug cost

$299,951

Median for Nurse Practitioner: $21,885

Branded share of claims

13.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 33 $122,371
Otezla Apremilast Brand 19 $88,494
Rinvoq Upadacitinib Brand 12 $72,620
Clobetasol Propionate Generic 64 $2,997
Fluorouracil Generic 29 $2,029
Ketoconazole Generic 128 $1,954
Metronidazole Generic 36 $1,953
Doxycycline Hyclate Generic 60 $1,663
Triamcinolone Acetonide Generic 118 $1,044
Tretinoin Generic 17 $965

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$70,824

Of which drugs: $230

Medicare patients

553

Average age 73

Services billed

2,554

356 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 25%
Ischemic heart disease 21%
Osteoporosis 17%
Cancer 15%
Chronic kidney disease 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 96 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OLUMIANT
$3,946 — —
Bimzelx
$2,486 — —
TREMFYA
$1,410 — —
SKYRIZI
$252 — —
SOTYKTU
$215 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

807 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record